218600-44-3 Usage
Description
Bardoxolone is a synthetic oleanane triterpenoid that possesses multifunctional activities in the regulation of cellular growth and differentiation. It is known for its ability to activate the transcription factor peroxisome proliferator activator receptor-γ (PPARγ), and its apoptotic effects in malignant cells occur independently of PPARγ. Bardoxolone is characterized by its tan solid chemical properties.
Uses
Used in Pharmaceutical Industry:
Bardoxolone is used as a potential therapeutic agent for the treatment of diabetic kidney diseases, cancer, and thromboembolic events. Its application is based on its ability to improve hyperglycemia, proteinuria, glomerulus structure, and serum creatine levels, which may contribute to the amelioration of these conditions.
Used in Cancer Treatment:
Bardoxolone is used as an anticancer agent due to its apoptotic effects on malignant cells, which occur independently of PPARγ. It has the potential to be employed in the treatment of various types of cancer, targeting the dysregulation of cellular growth and differentiation.
Used in Treatment of Diabetic Kidney Diseases:
Bardoxolone is used as a therapeutic agent for the improvement of hyperglycemia, proteinuria, and glomerulus structure in patients with diabetic kidney diseases. Its application aims to alleviate the symptoms and potentially slow the progression of the disease.
Used in Thromboembolic Event Treatment:
Bardoxolone is used as a potential treatment for thromboembolic events, leveraging its multifunctional activities in controlling cellular growth and differentiation, which may contribute to the prevention or reduction of blood clot formation and related complications.
Biological Activity
bardoxolone methyl, previously known as rta 402, is the lead molecule in reata's portfolio of antioxidant inflammation modulators (aims). the aims are potent inducers of the transcription factor nrf2, an important biological target that controls the production of many of the body's antioxidant and detoxification enzymes. because oxidative stress and inflammation occur throughout the course of chronic kidney disease (ckd) and are known to contribute to loss of kidney function, agents that activate the nrf2 pathway in patients with ckd may provide a novel method for preserving or improving kidney function. bardoxolone methyl is currently being investigated as a potential oral once-a-day treatment for ckd.
Check Digit Verification of cas no
The CAS Registry Mumber 218600-44-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,8,6,0 and 0 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 218600-44:
(8*2)+(7*1)+(6*8)+(5*6)+(4*0)+(3*0)+(2*4)+(1*4)=113
113 % 10 = 3
So 218600-44-3 is a valid CAS Registry Number.
InChI:InChI=1/C31H41NO4/c1-26(2)10-12-31(25(35)36)13-11-30(7)23(19(31)16-26)20(33)14-22-28(5)15-18(17-32)24(34)27(3,4)21(28)8-9-29(22,30)6/h14-15,19,21,23H,8-13,16H2,1-7H3,(H,35,36)/t19-,21-,23-,28-,29+,30+,31-/m0/s1
218600-44-3Relevant articles and documents
Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages
Honda, Tadashi,Rounds, BarbieAnn V.,Gribble, Gordon W.,Suh, Nanjoo,Wang, Yongping,Sporn, Michael B.
, p. 2711 - 2714 (1998)
New derivatives with electron-withdrawing substituents at the C-2 position of 3-oxoolean-1-en-28-oic acid were synthesized. Among them, 2- cyano-3,12-dioxoleam-1,9-dien-28-oic acid (CDDO) was 400 times more potent than previous compounds we have made as an inhibitor of production of nitric oxide induced by interferon γ in mouse macrophages (IC50, 0.4 nM). The potency of CDDO was similar to that of dexamethasone, although CDDO does not act through the glucocorticoid receptor.
Oleanolic acid derivative with conjugated diene structure C ring and preparation method and application thereof
-
Paragraph 0105-0108, (2020/07/21)
The invention belongs to the field of medicinal chemistry, and particularly relates to an oleanolic acid derivative with a conjugated diene structure C ring and a preparation method and application thereof. In particular, the invention also provides a pharmaceutical composition comprising an effective amount of the derivative or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; moreover, the derivative or the pharmaceutically acceptable salt thereof can be used for treating inflammation-related diseases and has antitumor activity, and the safety of the compound is improved or equivalent.
Therapeutic compounds and methods of use
-
Page/Page column 13-14, (2016/03/26)
Compounds and methods useful for chemopreventative treatment of diseases such as cancer, Alzheimer's disease, Parkinson's disease, inflammatory bowel diseases, and multiple sclerosis.